Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 7, 641–642 (1 August 2008) | doi:10.1038/nrd2654
Certolizumab pegol
&
Abstract
In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
